Joe Jordan

Now gradually recovering. Today 500 GBP

20$ at January end

Now is 1.05 USD

Target 1900

Russia and Belarus alone produce 30% of all the world's fertilizer. K&S will continue to increase significantly over the medium term. It still has an affordable price.

Where can it go? Now around 23 euro

Time to recover from COVID and fly versus 10 euros (now less then 7)

other good news: Russia announced it will stop exporting ammonium nitrate for two months. The chemical compound is used in the agriculture industry as a fertiliser to boost yields for crops like corn, cotton and wheat. Russia is reportedly responsible for around 62 percent of global production

ImmunoGen Stock Soars On Positive Data From Ovarian Cancer Drug TrialImmunoGen said mirvetuximab, its treatment for patients with platinum-resistant ovarian cancer, performed well in a pivotal SORAYA trial. Mirvetuximab had a confirmed objective response rate (ORR) of 32.4%, the drugmaker said, with a duration of response (DOR) of 5.9 months in the 106-person trial.

Analyst Matthew Caufield set a price target of $26 on the stock, outlining four reasons for doing so. The company's shares are currently 38% above Tuesday's close at $4.81 but initially rose to a high of $5.50. The first of the four reasons for the rating is Ocuphire's phase 3 MIRA-2 trial's positive topline results for Nyxol. The analyst said that it presents an "opportune timing to get into the name prior to further program validation," which it expects in the near term. He also said a key differentiation of using Nyxol was another positive for the stock, adding that Ocuphire's APX3330 treatment for diabetic retinopathy is undervalued. "With Ocuphire completing a reverse merger with legacy oncology platform Rexahn Pharmaceuticals, and listing on NASDAQ in November 2020, we maintain invest

EyePoint Pharma secures $100M capital raise via equity offering

Yesterday value moved from 14.0 to 21.5 and during the day moved back to 14.3 dollars

Shares of EyePoint Pharmaceuticals Inc. reached a new 52-week intraday high after the company reported positive data from its Phase 1 DAVIO study of EYP-1901 in Wet AMD and announced plans to move forward to additional Phase 2 clinical trials in 2022.

Now is 7.75

Marcus, at which amount do you reckon we should sell?

Any target price for the end of 2021?Now is 10.5 euro

Can this company go back to 80?

Can this company go back to 80?

Can this company go back to 15?

Which is the target in 1 year time? Now it is 1,37

Can this company go back to 5? Now it is around 2 but it has plenty of potential to fly

Can this company go back to 10? Now it is around 7 but it has plenty of potential to fly

Can this company go back to 11?Now it is 7 and it has plenty of potential to fly

Can this come back to 15? Now is around 10 but it has plenty of potential to fly

Any target price for TFF? Now is 17.10 USD